Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric and Young Adult Patients with Chronic Myeloid Leukemia in Tyrosine Kinase Inhibitor Era: A Study of the Korean Blood and Marrow Transplantation Registry
Cancer Research and Treatment · 15.04.2026 · 58 (2) · 632-641
DOI: 10.4143/crt.2024.1186 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Research and Treatment, erschienen am 15.04.2026. Verfasst von Hee Young Ju und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Protein Kinase Inhibitors, Leukemia, Myelogenous, Chronic, BCR-ABL Positive. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Purpose
Chronic myeloid leukemia (CML) in children, adolescents, and young adults is rare and differs from older adults. This study evaluated the outcomes of allogeneic hematopoietic stem cell transplantation (HSCT) in young Korean CML patients during the tyrosine kinase inhibitor (TKI) era.Materials and Methods A retrospective analysis of 35 CML patients aged < 40 years who underwent allogeneic HSCT from 2009 to 2019 was conducted using Korean Blood and Marrow Transplantation Registry data. Patients were grouped by age < 20 years at HSCT (group 1, n=15) and 20-40 years at HSCT (group 2, n=20). Survival outcomes including overall survival (OS), relapse-free survival (RFS), and event-free survival (EFS) were analyzed using the Kaplan-Meier method.
Results
The median time between diagnosis and HSCT was 8.9 months. All the patients achieved engraftment but platelet recovery was significantly slower in group 1 (p=0.034). Acute and chronic graft-versus-host disease occurred in 54.3% and 34.3%, respectively. Five-year OS, RFS, and EFS rates of total patients were 66.8%, 50.8%, and 47.6%, with better OS was observed in group 1 by multivariable analysis (p=0.048). Disease status at HSCT was a significant predictor of OS (p=0.028), RFS (p=0.003), and EFS (p=0.004). Disease progression occurred in 13 out of 35 patients (37.1%); treatment-related mortality accounted for 63.6% of deaths (7 out of 11).
Conclusion
When performed at a younger age, allogeneic HSCT result in superior outcome in CML. Achieving remission before HSCT is critical for improved outcomes, highlighting the importance of pretransplant remission via optimal TKI strategies and minimal residual disease monitoring.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
- Department of Pediatrics, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.
- Center for Pediatric Cancer, Department of Pediatrics, National Cancer Center, Goyang, Korea.
- Division of Pediatric Hematology and Oncology, Department of Pediatrics, Yonsei University College of Medicine, Seoul, Korea.
- Division of Pediatric Hematology/Oncology, Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine, Seoul, Korea.
- Department of Medicine, Yeungnam University College of Medicine, Daegu, Korea.
Zitieren
APA
Ju, H. Y., Choi, H. S., Park, H. J., Yoo, K. H., Lyu, C. J., Im, H. J., Kim, M. K., Mun, Y. C., Moon, J. H., Yoon, S. S., Lee, E., Lee, J. H., Lee, J. H., Chong, S. Y., Cheong, J. W., Won, S., & Korean Society of Blood and Marrow Transplantation (2026). Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric and Young Adult Patients with Chronic Myeloid Leukemia in Tyrosine Kinase Inhibitor Era: A Study of the Korean Blood and Marrow Transplantation Registry. Cancer Research and Treatment, 58(2), 632-641. https://doi.org/10.4143/crt.2024.1186
Vancouver
Ju HY, Choi HS, Park HJ, Yoo KH, Lyu CJ, Im HJ, et al. Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric and Young Adult Patients with Chronic Myeloid Leukemia in Tyrosine Kinase Inhibitor Era: A Study of the Korean Blood and Marrow Transplantation Registry. Cancer Research and Treatment. 2026;58(2):632-641. doi:10.4143/crt.2024.1186
BibTeX
@article{Ju2026,
author = {Ju, Hee Young and Choi, Hyoung Soo and Park, Hyeon Jin and Yoo, Keon Hee and Lyu, Chuhl Joo and Im, Ho Joon and Kim, Min Kyoung and Mun, Yeung-Chul and Moon, Joon Ho and Yoon, Sung-Soo and Lee, Eunyoung and Lee, Jae Hoon and Lee, Je-Hwan and Chong, So Young and Cheong, June-Won and Won, Seunghyun and Korean Society of Blood and Marrow Transplantation, Korean Society of Blood and Marrow Transplantation},
title = {Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric and Young Adult Patients with Chronic Myeloid Leukemia in Tyrosine Kinase Inhibitor Era: A Study of the Korean Blood and Marrow Transplantation Registry},
journal = {Cancer Research and Treatment},
year = {2026},
volume = {58},
number = {2},
pages = {632--641},
doi = {10.4143/crt.2024.1186}
}
EUVIMED